Special Issue "Recent Advances in the Fight against Respiratory Viruses"

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: 31 July 2023 | Viewed by 1093

Special Issue Editor

Department of Etiology and Epidemiology, National Influenza Centre, Smorodintsev Research Institute of Influenza, Saint Petersburg 197376, Russia
Interests: influenza; RSV and SARS-CoV-2 evolution; improvement of the sentinel and hospital surveillance; determination of risk factors for SARI; population immunity; recognition of new pathogen emergence; evaluation of influenza vaccines effectiveness; monoclonal antibodies; antigenic analysis of influenza viruses

Special Issue Information

Dear Colleagues,

Despite tremendous efforts in the fight against influenza and SARS-CoV-2 by development and wide application of contemporary vaccines and antivirals, many problems remain due to the high variability of pathogens, on the one hand, and the short duration of protective population immunity, on the other. The high rate of mutations in the surface glycoproteins of viruses allows new drift variants escaping from the established immunity and cause annual seasonal epidemics. Besides, global surveillance shows that periodically in different countries of the world, new, highly transmissible and pathogenic variants of influenza and SARS viruses emerge, causing high morbidity and mortality of population and imposing a significant disease burden worldwide, which continues to keep existing healthcare systems under pressure. One of the important element of severe pandemic counteraction is the surveillance for the existing highly pathogenic viruses and for emergence of new variants in human-animal interface. In addition to traditional epidemiology, we observe the growing interest to molecular epidemiology, which enables the determination of the origin of emergent strains and ways of its further spread at the local, country and global level.

In this regard, the purpose of this issue is to provide an up-to-date view in the field of:

  • The development and clinical trials of new vaccines, monoclonal antibodies and antivirals to influenza, RSV and SARS-CoV-2;
  • The results of surveillance for a wide range of respiratory viruses and their interaction on the cellular and population level;
  • Data on evaluation of the effectiveness of vaccines in the context of ongoing pathogen drift;
  • New approaches and advances in the development of highly sensitive rapid diagnostic tests for the early detection of pathogens;
  • Decoding of new viruses’ genetic structure;
  • Assessing the transmissibility and pathogenicity of agents and, ultimately, preliminary predicting the severity of upcoming epidemic events.

Prof. Dr. Anna A. Sominina
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • influenza virus
  • SARS-CoV-2
  • RSV, adenovirus, parainfluenza virus, rhinovirus, metapneumovirus
  • epidemiology
  • vaccine effectiveness
  • antivirals
  • rapid diagnosis
  • PCR—detection
  • surveillance
  • molecular epidemiology
  • next-generation sequencing
  • virus evolution

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Molecular Modeling of Viral Type I Fusion Proteins: Inhibitors of Influenza Virus Hemagglutinin and the Spike Protein of Coronavirus
Viruses 2023, 15(4), 902; https://doi.org/10.3390/v15040902 - 31 Mar 2023
Viewed by 727
The fusion of viral and cell membranes is one of the basic processes in the life cycles of viruses. A number of enveloped viruses confer fusion of the viral envelope and the cell membrane using surface viral fusion proteins. Their conformational rearrangements lead [...] Read more.
The fusion of viral and cell membranes is one of the basic processes in the life cycles of viruses. A number of enveloped viruses confer fusion of the viral envelope and the cell membrane using surface viral fusion proteins. Their conformational rearrangements lead to the unification of lipid bilayers of cell membranes and viral envelopes and the formation of fusion pores through which the viral genome enters the cytoplasm of the cell. A deep understanding of all the stages of conformational transitions preceding the fusion of viral and cell membranes is necessary for the development of specific inhibitors of viral reproduction. This review systematizes knowledge about the results of molecular modeling aimed at finding and explaining the mechanisms of antiviral activity of entry inhibitors. The first section of this review describes types of viral fusion proteins and is followed by a comparison of the structural features of class I fusion proteins, namely influenza virus hemagglutinin and the S-protein of the human coronavirus. Full article
(This article belongs to the Special Issue Recent Advances in the Fight against Respiratory Viruses)
Show Figures

Figure 1

Back to TopTop